Abstract
Background: Insulin-like growth factor binding protein-4 (IGFBP-4), a member of the insulin like growth factor (IGF) family, transports and regulates the activity of IGFs. Pregnancy associated protein-A (PAPP-A) has proteolytic activity towards IGFBP-4 and both have been associated with a variety of cancers, including lung. We aimed to evaluate the utility of IGFBP-4 and PAPP-A as potential biomarkers in lung cancer.
Materials and Methods: Eighty-three volunteers, including 60 patients with lung cancer and 23 healthy individuals, were included. Patients with lung cancer were selected based on treatment status, histological subgroup, and stage of the disease. Enzyme-linked immunosorbent assays were used to assess serum levels of IGFBP-4 and PAPP-A, whereas IGF-1 levels were measured using a chemiluminescent immunometric assay.
Results: Serum IGFBP-4 levels in all patient groups, regardless of treatment status and histological differences, were significantly higher than those in the control group (p < 0.005). However, serum PAPP-A levels in the untreated patient group were found to be higher than those in the control group, and this difference was not statistically significant (p = 0.086).
Conclusion: Serum PAPP-A and IGFBP-4 levels are elevated in lung cancer. However, IGFBP-4 may have a better potential than PAPP-A as a lung cancer biomarker.
Keywords
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.